An unchecked collapse in biotechnology would be a disaster for the U.S. A meltdown would halt development of life-saving medicines, derail promising science, wipe out high-paying jobs, and weaken one of the pillars of America's high-tech future. But there are ways to turn the industry around. READ»
"All of a sudden, biotechnology is not just what's medically necessary, but it's what can inspire us," says Reshma Shetty, cofounder of Boston-based startup Ginkgo BioWorks. And we must evolve how we view the science's purpose and participants.READ»
An Israeli biotechnology firm is betting that stem cells harvested from human placentas can help treat a host of diseases--and strengthen muscles in the process.READ»
San Francisco, Los Angeles, and San Diego are often referred to as the major U.S. biotech hubs. New York City, no longer content to remain king of media and finance, is determined to join the club. To that end, the NYCIF, Henry ...READ»
While Washington spends yet another day failing to reform health care, New York is hosting 250 companies that are actively pushing the envelope in the pharmaceutical, medical, and biotech fields. The UBS Global Life Sciences ...READ»
